Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,183.41 +51.31 (+0.08%) CMC Crypto 200
1,405.64 -12.23 (-0.86%)
OGN Jan 2026 10.000 call
- Zacks
Organon (OGN) Just Overtook the 20-Day Moving Average
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
- Business Wire
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
SHANGHAI, China & JERSEY CITY, N.J., May 24, 2024--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosumab) biosimilar candidate HLX14.
- Business Wire
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
JERSEY CITY, N.J., May 08, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the "Secured Notes") and $500 million of 7.875% senior unsecured notes due 2034 (the "Unsecured
